C
Context Therapeutics Inc. (CNTX)
NCM – Real Time Price. Currency in USD
2.48
+0.09 (3.77%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.48
+0.09 (3.77%)
At close: May 12, 2026, 4:00 PM EDT
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Karen Chagin M.D. | Chief Medical Officer |
| Mr. Alex C. Levit Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations |
| Mr. Jeffrey Liebman | Associate Director of Accounting |
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director |
| Ms. Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations |
| Ms. Jennifer Minai-Azary | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 10-Q | cntx-20260331.htm |
| 2026-05-01 | 8-K | cntx-20260430.htm |
| 2026-04-28 | DEFA14A | contexttherapeutics2026pro.htm |
| 2026-04-28 | ARS | cntx10-kdec312025.pdf |
| 2026-04-17 | PRE 14A | cntx-20260417.htm |
| 2026-04-02 | 8-K | cntx-20260402.htm |
| 2026-03-23 | S-8 | cntxs-82026.htm |
| 2026-03-13 | 8-K | cntx-20260311.htm |
| 2026-02-27 | 8-K | cntx-20260224.htm |
| 2026-01-08 | 8-K | cntx-20260108.htm |